All News
Opioids Ineffective in Acute Lower Back and Neck Pain
EurekAlert!
A randomised controlled trial including 347 participants with lower back or neck pain found there was no benefit of taking opioid pain relievers compared to placebo.
Read Article
How Often Do You Monitor MTX? (6.16.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening.
Read Article
Why Depression Screening Should be Mandatory at Each Visit
Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015.
Read Article
EULAR 2023 – Day 1 Report
EULAR 2023 launched today to crowds of attendees. The opening Plenary session and presidential address by Dr.
Read Article
c-Fos regulates chondrocyte proliferation and differentiation, and cFOS-positive chondrocytes were increased in human and murine OA cartilage. New research (humans an mice) suggests it plays a role in protecting cartilage and could be a therpeutic target https://t.co/B0tmo0AbQe https://t.co/KPrOm3Spfa
Links:
Dr. John Cush RheumNow ( View Tweet)
Ultrasonography May Improve OA Pain Prediction
Dr. Bella Mehta reports on POS0107 from EULAR 2023 in Milan, Italy.
https://t.co/ZHBdWPWTys https://t.co/JLIScNVZGB
Links:
Dr. John Cush RheumNow ( View Tweet)
Australian CRISTAL RCT 23 458 OA adults undergoing hip or knee replacements & given ASA 100 mg/d or SC enoxaparin 40 mg qd for 35 days (THR) or 14 days(TKR) for VTE prophylaxis = no difference betw groups: 90D mortality was 1.67% vs 1.53% https://t.co/wBLtlyCcsF https://t.co/WFkZ2KNHFF
Links:
Dr. John Cush RheumNow ( View Tweet)
519 pts in the Hand OSTeoArthritis in Secondary care (HOSTAS) cohort studied & 17% had prolonged morning stiffness (>60 min); mild in 30%, intermediate in 37%, severe in 18% and extreme in 4%. Assoc w/ more pain, worse function and QOL https://t.co/6LSir7nSae https://t.co/lhoxwpfuqD
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Denosumab in hand OA prevented erosions!
#eular2023 @RheumNow https://t.co/Ij2CVjh1ET
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nocicpetor ablation in mice model with #OA - pain was reduced.
If its done before OA progression, it helps, but after it doesnt!
@AM_Malf work highligted at #EULAR2023 @RheumNow https://t.co/zvxHmlCIrD
Bella Mehta bella_mehta ( View Tweet)
We need to assess CV risk in IA but how?
Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO
Bummer: these 3 prediction tools are less accurate in IA but also OA.
We need a dedicated tool.
@Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
Aurelie Najm AurelieRheumo ( View Tweet)
Interesting study presented by Dr Kent Kwoh in #KneeOA using the OAI data - effusion-synovitis produced heterogenous effects on pain reporting depending on the activity - walking, stairs, standing etc. effect not in bone marrow lesions
@rheumnow abst#POS0108 #EULAR2023 https://t.co/MvI5z1KHlE
Bella Mehta bella_mehta ( View Tweet)
Phase 2b-human Knee #OA MM-II, a novel suspension of empty large multilamellar liposomes dimyristoylphosphatidylcholine (DMPC)and dipalmitoylphosphatidylcholine (DPPC)- upto 6ml IA injection - well tolerated with minimal AE. some effect on WOMAC @rheumnow #EULAR2023 abs#POS0106 https://t.co/MM8jIG5bkP
Bella Mehta bella_mehta ( View Tweet)
Erosive #handOA is associated with more pain and more functional impairment than #RA - 10 year duration, which ofcourse has more comorbidities. 138 OA, 379 RA pts. #EULAR2023 @rheumnow abst#POS0103 https://t.co/mP3Nzgmw07
Bella Mehta bella_mehta ( View Tweet)
Would you rather have Erosive hands OA or RA?
130+ EHOA and 370+ RA, dis duration > 10 yrs for both cohorts
📍EHOA associated w/ > pain & functional impairment
📍RA associated w/ > comorbidities
@RheumNow #EULAR23 POS0103 https://t.co/KdDG7E6PZw
Aurelie Najm AurelieRheumo ( View Tweet)
Fluorescence optical imaging in early arthritis?
Nice images but not ready for clinics yet
Can not differentiate OA from RA & PsA
SLE/SSc associated arthritis display a specific pattern, but usually auto-antibody profiles help w/ diagnosis
OP0173 #EULAR23 @Rheunow https://t.co/bAMi9kDKS5
Aurelie Najm AurelieRheumo ( View Tweet)
What would you do? A middle aged woman has pain and impaired hand function with her PIP&DIP erosive hand #osteoarthritis? Exam - jts are tender w soft tissue swelling? #NSAIDs, #denosumab, #methotrexate? 🤷♀️ A +RCT of #MTX in #erosive #hand #OA at #EULAR2023 @RheumNow @eular_org https://t.co/7rp3nReTPd
Janet Pope Janetbirdope ( View Tweet)
Are we going to treat hands OA with MTX?
Moderate effect on VAS pain at 6 and 12 months in a small RCT vs. PBO in hands OA WITH MRI detected synovitis.
Thoughts
1) Is it really OA?
2) Benefit Risk balance remains debatable
@RheumNow OP0070 #EULAR23 https://t.co/WLlX48NtGT
Aurelie Najm AurelieRheumo ( View Tweet)
